Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Covid

<< Previous

Bullboard Posts

Next >>

Comment by Amazighon Sep 17, 2021 6:12pm

98 Views

Post# 33882034

RE:RE:RE:RE:RE:RE:RE:RE:RE:Covid

Sacloco wrote: Your very welcome. Kids need a little guidance, don't spend all allowance tho. Did great on Zena, shorted it all the way from around $6 till the Hexo buyout..but thanks for your concern ..

Forget my earlier comment, and by all means come and short CLAS. Love to see that Zena money of yours wasted in a short squeeze

<< Previous

Bullboard Posts

Next >>

Cizzle Brands, Changing Consumer Habits in Consumables